Swiss National Bank boosted its stake in Haemonetics Co. (NYSE:HAE) by 1.6% during the second quarter, HoldingsChannel reports. The institutional investor owned 93,100 shares of the medical instruments supplier’s stock after buying an additional 1,500 shares during the quarter. Swiss National Bank’s holdings in Haemonetics were worth $8,349,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the stock. BlackRock Inc. lifted its stake in Haemonetics by 3.8% in the first quarter. BlackRock Inc. now owns 6,924,926 shares of the medical instruments supplier’s stock valued at $506,627,000 after acquiring an additional 253,938 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Haemonetics by 1,765.9% in the first quarter. Millennium Management LLC now owns 1,183,544 shares of the medical instruments supplier’s stock worth $86,588,000 after buying an additional 1,120,115 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Haemonetics by 28.3% in the second quarter. Acadian Asset Management LLC now owns 888,097 shares of the medical instruments supplier’s stock worth $79,646,000 after buying an additional 196,154 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Haemonetics by 18.4% in the second quarter. Bank of New York Mellon Corp now owns 785,681 shares of the medical instruments supplier’s stock worth $70,460,000 after buying an additional 122,168 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Haemonetics by 1.1% in the first quarter. Northern Trust Corp now owns 684,071 shares of the medical instruments supplier’s stock worth $50,047,000 after buying an additional 7,372 shares during the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.
In other news, CFO William P. Mr. Burke sold 6,687 shares of the business’s stock in a transaction on Monday, June 25th. The shares were sold at an average price of $92.17, for a total value of $616,340.79. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Christopher Simon sold 3,595 shares of the business’s stock in a transaction on Friday, June 29th. The shares were sold at an average price of $40.39, for a total transaction of $145,202.05. The disclosure for this sale can be found here. Insiders sold a total of 16,880 shares of company stock worth $1,284,307 in the last three months. Insiders own 1.04% of the company’s stock.
Shares of HAE stock opened at $111.14 on Thursday. Haemonetics Co. has a 1 year low of $41.54 and a 1 year high of $112.82. The firm has a market cap of $5.77 billion, a P/E ratio of 59.43, a P/E/G ratio of 4.59 and a beta of 1.01. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.94 and a current ratio of 2.84.
Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Tuesday, August 7th. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.42 by $0.17. The firm had revenue of $229.35 million for the quarter, compared to analyst estimates of $219.52 million. Haemonetics had a net margin of 2.45% and a return on equity of 15.00%. analysts predict that Haemonetics Co. will post 2.28 EPS for the current year.
HAE has been the subject of a number of analyst reports. Morgan Stanley boosted their price objective on shares of Haemonetics from $100.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 8th. Jefferies Financial Group boosted their price objective on shares of Haemonetics from $95.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, June 14th. Zacks Investment Research upgraded shares of Haemonetics from a “hold” rating to a “buy” rating and set a $105.00 price objective for the company in a research note on Tuesday, June 12th. Barrington Research boosted their price objective on shares of Haemonetics from $90.00 to $118.00 and gave the stock an “outperform” rating in a research note on Thursday, August 9th. Finally, TheStreet lowered shares of Haemonetics from a “b” rating to a “c+” rating in a research report on Monday, August 20th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Haemonetics has a consensus rating of “Buy” and a consensus target price of $98.33.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Featured Article: Understanding Analyst Recommendations
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.